107 related articles for article (PubMed ID: 20551242)
21. Acetaminophen inhibits intestinal p-glycoprotein transport activity.
Novak A; Carpini GD; Ruiz ML; Luquita MG; Rubio MC; Mottino AD; Ghanem CI
J Pharm Sci; 2013 Oct; 102(10):3830-7. PubMed ID: 23897240
[TBL] [Abstract][Full Text] [Related]
22. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.
Huisman MT; Smit JW; Wiltshire HR; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2003 Feb; 304(2):596-602. PubMed ID: 12538811
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.
Gnoth MJ; Buetehorn U; Muenster U; Schwarz T; Sandmann S
J Pharmacol Exp Ther; 2011 Jul; 338(1):372-80. PubMed ID: 21515813
[TBL] [Abstract][Full Text] [Related]
24. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.
Polli JW; Jarrett JL; Studenberg SD; Humphreys JE; Dennis SW; Brouwer KR; Woolley JL
Pharm Res; 1999 Aug; 16(8):1206-12. PubMed ID: 10468021
[TBL] [Abstract][Full Text] [Related]
25. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
26. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
Ohashi R; Kamikozawa Y; Sugiura M; Fukuda H; Yabuuchi H; Tamai I
Drug Metab Dispos; 2006 May; 34(5):793-9. PubMed ID: 16455807
[TBL] [Abstract][Full Text] [Related]
27. PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.
Holmstock N; Gonzalez FJ; Baes M; Annaert P; Augustijns P
Mol Pharm; 2013 Mar; 10(3):1056-62. PubMed ID: 23360470
[TBL] [Abstract][Full Text] [Related]
28. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
Acharya P; O'Connor MP; Polli JW; Ayrton A; Ellens H; Bentz J
Drug Metab Dispos; 2008 Feb; 36(2):452-60. PubMed ID: 17967933
[TBL] [Abstract][Full Text] [Related]
29. Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors.
Coburger C; Lage H; Molnár J; Langner A; Hilgeroth A
J Pharm Pharmacol; 2010 Dec; 62(12):1704-10. PubMed ID: 21054396
[TBL] [Abstract][Full Text] [Related]
30. Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Chu C; Abbara C; Noël-Hudson MS; Thomas-Bourgneuf L; Gonin P; Farinotti R; Bonhomme-Faivre L
Biochem Pharmacol; 2009 May; 77(10):1629-34. PubMed ID: 19426700
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.
Lee CG; Gottesman MM; Cardarelli CO; Ramachandra M; Jeang KT; Ambudkar SV; Pastan I; Dey S
Biochemistry; 1998 Mar; 37(11):3594-601. PubMed ID: 9530286
[TBL] [Abstract][Full Text] [Related]
32. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Tong L; Phan TK; Robinson KL; Babusis D; Strab R; Bhoopathy S; Hidalgo IJ; Rhodes GR; Ray AS
Antimicrob Agents Chemother; 2007 Oct; 51(10):3498-504. PubMed ID: 17664327
[TBL] [Abstract][Full Text] [Related]
33. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects.
Vermeir M; Lachau-Durand S; Mannens G; Cuyckens F; van Hoof B; Raoof A
Drug Metab Dispos; 2009 Apr; 37(4):809-20. PubMed ID: 19131522
[TBL] [Abstract][Full Text] [Related]
34. Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits.
Sinko PJ; Kunta JR; Usansky HH; Perry BA
J Pharmacol Exp Ther; 2004 Jul; 310(1):359-66. PubMed ID: 15004217
[TBL] [Abstract][Full Text] [Related]
35. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
36. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
Varma MV; Sateesh K; Panchagnula R
Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
[TBL] [Abstract][Full Text] [Related]
37. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
Capel E; Auclair M; Caron-Debarle M; Capeau J
Antivir Ther; 2012; 17(3):549-56. PubMed ID: 22293506
[TBL] [Abstract][Full Text] [Related]
38. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth MJ; Sandmann S; Engel K; Radtke M
Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
[TBL] [Abstract][Full Text] [Related]
39. In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results.
González-Alvarez I; Fernández-Teruel C; Casabó-Alós VG; Garrigues TM; Polli JE; Ruiz-García A; Bermejo M
Biopharm Drug Dispos; 2007 Jul; 28(5):229-39. PubMed ID: 17410527
[TBL] [Abstract][Full Text] [Related]
40. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability.
Varma MV; Panchagnula R
J Pharm Sci; 2005 Aug; 94(8):1694-704. PubMed ID: 15986467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
